Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Nitric-oxide synthase, brain | References | |
Homo sapiens | nitric oxide synthase 1 (neuronal) | References | |
Mus musculus | nitric oxide synthase 2, inducible | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | p450 reductase, putative | 0.0086 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0086 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0076 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0086 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0086 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0076 | 0.7743 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0053 | 0.2407 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0043 | 0 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0086 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0086 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0086 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0086 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0086 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0043 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0086 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0086 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0086 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0053 | 0.2407 | 0.2407 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0086 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0086 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0086 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0086 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0086 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0086 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0086 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0043 | 0.0151 | 0.0151 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0086 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0086 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 43 nM | Inhibition of rat recombinant nNOS expressed in Escherichia coli using L-arginine as substrate assessed as reduction in NO production measured for 6 mins in presence of tetrahydrobiopterin by hemoglobin capture assay | ChEMBL. | 27050842 |
Ki (binding) | = 84 nM | Inhibition of human recombinant nNOS expressed in Escherichia coli using L-arginine as substrate assessed as reduction in NO production measured for 6 mins in presence of tetrahydrobiopterin by hemoglobin capture assay | ChEMBL. | 27050842 |
Ki (binding) | = 14214 nM | Inhibition of recombinant mouse macrophage iNOS expressed in Escherichia coli using L-arginine as substrate assessed as reduction in NO production measured for 6 mins by hemoglobin capture assay | ChEMBL. | 27050842 |
Ki (binding) | > 30000 nM | Inhibition of bovine recombinant eNOS expressed in Escherichia coli using L-arginine as substrate assessed as reduction in NO production measured for 6 mins in presence of tetrahydrobiopterin by hemoglobin capture assay | ChEMBL. | 27050842 |
Ki (binding) | = 73006 nM | Inhibition of human recombinant eNOS expressed in Escherichia coli using L-arginine as substrate assessed as reduction in NO production measured for 6 mins in presence of tetrahydrobiopterin by hemoglobin capture assay | ChEMBL. | 27050842 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.